ARK Investment Management Boosts Stake in Illumina

Institutional investor increases position in life sciences company by 25.7%

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

ARK Investment Management LLC grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 25.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor now owns 1,467,879 shares of the life sciences company's stock, valued at approximately $139.41 million.

Why it matters

Illumina is a leading provider of DNA sequencing systems and related products, playing a key role in the growing field of genomics. ARK Investment Management's increased stake in the company signals the firm's confidence in Illumina's long-term growth potential as the demand for genetic analysis and personalized medicine continues to rise.

The details

According to the filing, ARK Investment Management purchased an additional 299,801 shares of Illumina during the third quarter, bringing its total ownership to approximately 0.96% of the company's outstanding shares. The investment firm is known for its focus on disruptive innovation and has been a major investor in Illumina for several years.

  • ARK Investment Management disclosed its increased stake in Illumina in a filing with the SEC on March 5, 2026.

The players

ARK Investment Management LLC

An American investment management firm focused on disruptive innovation, managing several actively-managed exchange-traded funds (ETFs).

Illumina, Inc.

A global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function.

Got photos? Submit your photos here. ›

The takeaway

ARK Investment Management's increased stake in Illumina underscores the firm's belief in the long-term growth potential of the life sciences company as genetic analysis and personalized medicine continue to gain traction. This move highlights the institutional investor's confidence in Illumina's ability to capitalize on emerging trends in the genomics space.